Midazolam Accord (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion influx into neurons. This heightened inhibitory signaling leads to reduced neuronal excitability, producing sedation, anxiolysis, muscle relaxation, and seizure control.

The dose of Midazolam Accord is determined by the prescribing clinician based on the indication, patient age, weight, and clinical condition. Healthcare professionals adjust the amount to achieve the desired level of sedation or seizure control.

Midazolam is classified as a pregnancy category C medication in many regions, indicating potential risk. It can pass into breast milk. Use during pregnancy or lactation should only occur when the benefit outweighs the risk and under strict medical supervision.

To order Midazolam Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Midazolam has a rapid onset of action and a relatively short duration compared with agents like diazepam or lorazepam. This makes it especially useful for short procedures or emergency seizure control, whereas longer‑acting benzodiazepines are often chosen for chronic anxiety or insomnia.

Midazolam Accord should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Midazolam Accord is administered by injection via the intramuscular, intravenous, or rectal route, depending on the clinical situation. The route and rate of administration are selected by the healthcare professional to achieve the intended therapeutic effect.

The most serious risks include respiratory depression, severe hypotension, and rare allergic reactions such as anaphylaxis. Continuous monitoring of breathing and cardiovascular status is essential, especially when higher doses or concurrent CNS depressants are used.

Midazolam should be avoided in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, or those who are pregnant without a clear medical indication. Clinicians must evaluate each patient’s medical history before prescribing.